Cargando…

A rapid decline in the anti–receptor-binding domain of the SARS-CoV-2 spike protein IgG titer in kidney transplant recipients after tixagevimab–cilgavimab administration

Detalles Bibliográficos
Autores principales:	Benotmane, Ilies, Velay, Aurélie, Vargas, Gabriela-Gautier, Olagne, Jérôme, Cognard, Noëlle, Heibel, Françoise, Braun-Parvez, Laura, Martzloff, Jonas, Perrin, Peggy, Pszczolinski, Romain, Moulin, Bruno, Fafi-Kremer, Samira, Caillard, Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Society of Nephrology. Published by Elsevier Inc. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375643/ https://www.ncbi.nlm.nih.gov/pubmed/35973595 http://dx.doi.org/10.1016/j.kint.2022.07.022

Ejemplares similares

Prediction of Vaccine Response and Development of a Personalized Anti-SARS-CoV-2 Vaccination Strategy in Kidney Transplant Recipients: Results from a Large Single-Center Study
por: Benotmane, Ilies, et al.
Publicado: (2022)

Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients
por: Benotmane, Ilies, et al.
Publicado: (2021)

Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine
por: Benotmane, Ilies, et al.
Publicado: (2021)

Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant
por: Benotmane, Ilies, et al.
Publicado: (2022)

Persistence of SARS-CoV-2 antibodies in kidney transplant recipients
por: Benotmane, Ilies, et al.
Publicado: (2021)

COVID-19 in a kidney transplant recipient treated with eculizumab for atypical hemolytic uremic syndrome: a case report
por: Cognard, Noëlle, et al.
Publicado: (2021)

Tixagevimab + Cilgavimab: First Approval
por: Keam, Susan J.
Publicado: (2022)

Impaired P2Y12 inhibition by clopidogrel in kidney transplant recipients: results from a cohort study
por: Muller, Clotilde, et al.
Publicado: (2016)

Tixagevimab and cilgavimab for COVID-19 prophylaxis
Publicado: (2022)

Molecular evolution of the SARS-CoV-2 omicron BA.2 variant in kidney transplant recipients with prolonged viral shedding
por: Caillard, Sophie, et al.
Publicado: (2023)

Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab
por: Gautier-Vargas, Gabriela, et al.
Publicado: (2020)

Tixagevimab/ Cilgavimab Outcomes Among Patients with Immunodeficiency
por: Sullivan, Juliana
Publicado: (2023)

Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients
por: Charmetant, Xavier, et al.
Publicado: (2022)

A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients
por: Benotmane, Ilies, et al.
Publicado: (2022)

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
por: Levin, Myron J., et al.
Publicado: (2022)

Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections
por: Dichtl, Stefanie, et al.
Publicado: (2022)

A case of prolonged COVID‐19 treated with tixagevimab/cilgavimab
por: Shimizu, Takahiro, et al.
Publicado: (2023)

Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
por: Chen, Benjamin, et al.
Publicado: (2023)

Prédiction de la sévérité de la COVID-19 par les biomarqueurs du syndrome de relargage cytokinique au sein d’une population de transplantés rénaux
por: Benotmane, I., et al.
Publicado: (2020)

Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies
por: Ocon, Anthony J., et al.
Publicado: (2022)

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
por: Zamprogna, Giulia, et al.
Publicado: (2023)

Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases
por: Otiniano, Armelle, et al.
Publicado: (2022)

Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
por: Aqeel, Faten, et al.
Publicado: (2022)

Cardiac and vascular serious adverse events following tixagevimab–cilgavimab – Author's reply
por: Maselkar, Sheetal, et al.
Publicado: (2023)

Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab
por: Solera, Javier T, et al.
Publicado: (2023)

P1574: EFFICACY AND SAFETY OF TIXAGEVIMAB AND CILGAVIMAB (EVUSHELD) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Aleshina (Gavrilina), Olga, et al.
Publicado: (2023)

1339. Effects of Tixagevimab-Cilgavimab in Clinical Practice is Consistent with Preliminary Neutralization Studies
por: Dluzynski, Daniela, et al.
Publicado: (2023)

INCIDENCE OF COVID-19 INFECTIONS IN ADULTS WITH PRIMARY IMMUNODEFICIENCY AFTER RECEIVING TIXAGEVIMAB AND CILGAVIMAB
por: Johnson, S., et al.
Publicado: (2022)

Tixagevimab and Cilgavimab (Evusheld – AstraZeneca) efficacy in preventing COVID infection in immunocompromised patients
por: Miot, Christelle, et al.
Publicado: (2023)

Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients
por: Fernández-Prada, María, et al.
Publicado: (2023)

AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019
por: Levin, Myron J, et al.
Publicado: (2022)

(653) Tixagevimab and Cilgavimab Reduced the Likelihood of Covid after Heart Transplant in the Age of Omicron
por: Lee, R., et al.
Publicado: (2023)

498. Covid-19 Hospitalization Rates in Kidney Transplant Patients Treated with Tixagevimab/Cilgavimab
por: Dugan, Katherine, et al.
Publicado: (2023)

Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment
por: Vellas, Camille, et al.
Publicado: (2022)

Increased reporting of venous and arterial thromboembolic events reported with tixagevimab–cilgavimab for coronavirus disease 2019
por: Montastruc, François, et al.
Publicado: (2023)

Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies
por: Davis, James A., et al.
Publicado: (2023)

The effect of tixagevimab-cilgavimab on clinical outcomes in patients with COVID-19: A systematic review with meta-analysis
por: Wang, Yong, et al.
Publicado: (2023)

Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients
por: Nguyen, Yann, et al.
Publicado: (2022)

‘Real-World’ Impact of Tixagevimab/Cilgavimab (Evusheld) on COVID-19 Outcomes in Patients Undergoing Cellular Therapies
por: Sannareddy, Aishwarya, et al.
Publicado: (2023)

Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity
por: Johnson, Sarah, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_js4efr5g2daks7bv6q1kau628f